Everest Medical
This article was originally published in The Gray Sheet
Executive Summary
Receives $800,000 equity investment from a private investor through the sale of 290,909 units at $2.75 each. The units consist of one share of unregistered common stock and one warrant to purchase a share of unregistered common stock for $3.50. The company had announced Jan. 21 that it was seeking financing from "numerous corporate and private sources" to continue operations ("The Gray Sheet" Feb. 1, p. 14). Everest Medical Chairman Michael Hollenhorst says in a Feb. 8 release that the recent investment "provides us with necessary working capital which will help us to cover operating expenses as we roll out our laparoscopic surgical scissors and forceps." The company "will require additional capital, which is being sought from various sources." The minimally invasive surgery products manufacturer says it has taken steps to "further reduce" its operating expenses and expects to make "additional spending and staff reductions." The company believes the reductions can be made "without significantly jeopardizing" sales and development activities. The firm also announced Feb. 8 that it has received notice from its Japanese distributor, Koshin International, that Japan's Ministry of Health has granted approval for Koshin to commence promotion and sales of Everest Medical's Evershears bipolar laparoscopic scissors in Japan.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.